Research progress of melatonin on pulmonary hypertension
10.12092/j.issn.1009-2501.2021.04.012
- Author:
Rui WANG
1
;
Jinjin PAN
1
;
Yuhui YUAN
1
;
Rui WANG
2
;
Rui WANG
3
;
Hua LI
3
Author Information
1. Institute of Cancer Stem Cell, Dalian Medical University University
2. Department of Hematology, The Second Hospital of Dalian Medical University
3. College of Pharmacy, Dalian Medical University
- Publication Type:Journal Article
- Keywords:
Anti-inflammation;
Anti-oxidation;
Melatonin;
Pulmonary hypertension
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(4):444-448
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary hypertension is a severe disease with a wide spectrum of underlying etiologies, which was characterized by increased pulmonary arterial pressure and pulmonary vascular resistance, and eventually leads to right heart dysfunction and even death with a high mortality rate. Melatonin, as a neuroendocrine hormone, is produced primarily by the pineal gland. Melatonin, a pleotropic molecule, plays a key role in the pathophysiology of various cardiovascular diseases.The effects of melatonin which can attenuate pulmonary vascular remodeling and pulmonary artery pressure have been widely concerned by researchers in recent years. This review summarized the progress of melatonin on pulmonary hypertension.
